Sebela Pharmaceuticals
Developing therapies for gastrointestinal diseases and women's health
Based in GA
🤖
AI Overview
With $400K in lobbying spend across 11 quarterly filings, Sebela Pharmaceuticals is an active lobbying client. Their lobbying covers 1 issue area. Active from 2023 to 2025.
$400K
Total Spend
3
Years Active
1
Firms Hired
2
Lobbyists Deployed
1
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2023 | $40K |
| 2024 | $160K |
| 2025 | $200K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
- •general healthcare issues; coverage for prescription bowel prep products
- •Affordable Care Acts Preventative Services Coverage mandate requires ACA compliant health plans to cover colonoscopy screenings without cost sharing . In 2016, CMS released guidance clarifying that bo
- •The Affordable Care Acts Preventive Services Coverage mandate requires ACA-compliant health plans to cover colonoscopy screenings without cost sharing. In 2016, CMS issued guidance clarifying that bow
- •Discussed the need for Congressional oversight of CMS to ensure enforcement of the preventive services mandate, specifically requiring coverage of bowel preparation medications without cost-sharing wh
- •Requesting CMS change guidance on Bowel Prep Coverage for Screening Colonoscopies
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.